

Sartar

NOVEL TARGETED THERAPY FOR GASTROINTESTINAL STROMAL TUMOR

.....

The focus of cancer therapy is moving towards personalized medicine that has revolutionized treatments of certain cancers, including GIST. Although new GIST therapies have been efficacious and have improved disease outcomes of the patients significantly, they fail frequently and the disease progresses. Therefore, there is a dire need for finding new therapies for GIST patients.

Sartar Therapeutics is developing a new therapeutic option for GIST patients based on drug reformulation and repositioning of anagrelide, the drug that has been used to treat thrombocytopenia, a blood disease characterized by platelet overproduction. Anagrelide will be reformulated into a slow-release drug product. Reformulation will improve pharmacokinetic properties of the candidate product to make it more efficacious, better tolerated and more convenient for use in therapy.

SPARK VALUE Through the SPARK program, we have met life science experts who have provided us valuable instructions and mentoring at the early stages of the company. SPARK has also helped us to gain international visibility through global SPARK networks that helps us to find potential international collaborators and investors.



Harri Sihto, Ph.D.

ADJUNCT PROFESSOR OF CANCER BIOLOGY, WHOSE RESEARCH FOCUSES ON RARE CANCERS

The Chairman of the Board, Dr. Harri Sihto is a founding member of the Company. He is a biochemist in the University of Helsinki. His research has focused on molecular cancer research and rare cancers for 15 years. Dr. Sihto is responsible for the management of the company at present.

Heikki Joensuu, M.D., Ph.D.

PROFESSOR OF ONCOLOGY AND THE KEY OPINION LEADER OF GIST THERAPIES

The Professor Heikki Joensuu (University of Helsinki & Helsinki University Hospital) is a founder and board member of the Company. He is an oncologist recognized worldwide and has received many scientific awards for improving and developing cancer care. He treated the first GIST patient with imatinib and was the senior investigator in the first randomized trial carried out with imatinib in advanced GIST.



Olli-Pekka Pulkka, M.Sc.

PH.D. STUDENT, AN EXPERT IN PDE3 BIOLOGY

Olli-Pekka Pulkka is a founder and board member of the Company. He is a molecular biologist in the University Helsinki. His research is focused on the prognostic factors and novel therapeutic targets in GIST. Mr. Pulkka is preparing his PhD thesis on the role of PDE3 as a therapy target in GIST.

Olli Kallioniemi, M.D., Ph.D.

AN INNOVATIVE PROFESSOR OF MOLECULAR PRECISION MEDICINE

Professor Olli Kallioniemi is a founder and board member of Sartar Therapeutics. Professor Kallioniemi is an expert in a precision medicine. As a founding director of the Institute of Molecular Medicine Finland, he had a crucial role in building a national research infrastructure required for precision medicine research. At the moment, Professor Kallioniemi is appointed as Director of SciLifeLab, Sweden.

